Doses of Coffee and Blood Pressure Response Post-exercise

January 7, 2015 updated by: Alesandra Araújo de Souza, Federal University of Paraíba

Influence of Different Doses of Coffee in the Blood Pressure Response Post-exercise

Introduction: reduction of blood pressure after physical exercise is called post exercise hypotension (PEH). However, previous studies demonstrate that ingestion of caffeine equivalent to three tea-cup of coffee abolishes this phenomenon. Objective: evaluate the influence of different doses of coffee in PEH. Methods: eleven hypertensive performed four experimental sessions of aerobic exercise in cycle ergometer (40 minutes of duration, intensity between 60% and 80% of maximum heart rate) succeeds for the ingestion of one (CAF-1), two (CAF-2), three (CAF-3) doses of caffeinated coffee (144 mg/dose), or three doses of decaffeinated coffee (DESC). Blood pressure was measured in rest and during 120 minutes of recovery post exercise, each 10 minutes.

Study Overview

Detailed Description

Volunteers: participated 12 volunteers diagnosed as hypertensive, both gender (three men), 40 to 55 years old, overweight and practitioners of aerobic exercise (walk) at least three months. They were treated with anti-hypertensive medication of class beta-adrenergic receptor blockers, thiazides and enzyme convertor of angiotensin inhibitors, and showing systolic and diastolic pressoric values controlled and habituated to coffee consumption. Would be excluded from the study volunteers who presented migraine or other withdrawal symptoms due to a washout to be carried out for coffee and other caffeinated foods. The volunteers participated of this study for average one month. This study was previously approved by Ethic Committee in Search with Humans at Hospital Lauro Wanderley, at Federal University of Paraiba, under protocol 21/2011. All volunteers was previously clarified about the experimental procedures, and they signed the written informed consent according resolution 466/12 at Health National Council (Brazil).

Design of Study: the study was experimental, randomized and double-blind. Before the experimental sessions the volunteers were instructed to avoid caffeinated foods during 48 hours. They performed four experimental sessions with the practice of aerobic exercise, succeed for the ingestion of caffeinated or decaffeinated coffee, according to following protocols: 1) one dose of 150 ml of coffee (144 mg of caffeine) ingested 10 minutes post-exercise (CAF-1); 2- two doses of 150 ml of coffee (2x144 mg of caffeine) ingested 10 and 20 minutes post-exercise (CAF-2); three doses of 150ml of coffee (3x 144 mg of caffeine) ingested 10, 20 and 30 minutes post-exercise (CAF-3); 4- three doses of 150 ml of decaffeinated coffee (108 mg of caffeine) ingested 10, 20 and 30 minutes post-exercise (DESC). The order of realization experimental sessions was determined randomly through the site www.randomizer.org. They remained seated during 120 minutes after exercise. Blood pressure was evaluated in rest, and during 120 minutes of post-exercise recovery, each 10 minutes.

Preparation and Ingestion of coffee: was utilized one caffeinated and decaffeinated coffee (São Braz, Cabedelo, Brazil) with one same serial number. Caffeinated and decaffeinated coffee had 1,2% and 0,3% of caffeine, respectively, in your composition. The method adopted to the preparation of caffeinated or decaffeinated coffee was previously utilized for Nóbrega et al. (15). Were prepared with addition of 40g coffee powder to each 500 ml of heated water during five minutes, limited by beginning of boil. Thus, the volume of 500 ml of coffee had one concentration of 480 mg of caffeine. Considering each tea-cup ingested had one volume of 150 ml, so one, two and three tea-cups with coffee had respectively 144 mg, 288 mg and 432 mg of caffeine. Three tea-cups of decaffeinated coffee were 108 mg of caffeine. The doses of caffeinated or decaffeinated coffee were sweetened with sugar (Alegre, Mamanguape, Brazil). The coffee was strained with filters paper (Mellita®, Minden, Alemanha). To ensure the accuracy of volume intake by volunteers at all time was utilized one dosing tea-cup previously calibrated to volume of one tea-cup (150 ml). The intake coffee was performed on first 30 minutes of period recovery, each 10 minutes. During moment of ingestion, volunteers stay seated and was stipulated a deadline of five minutes to intake the coffee.

Protocol of Physical Exercise: volunteers performed four experimental sessions with aerobic exercise on a stationary bicycle (Perform V3, Movement®, Pompeia, Sao Paulo), lasting 40 minutes, intensity between 60 and 80% of maximum heart rate (MHR). To estimate of MHR was utilized the equation proposed by Bruce et al. (16). To the prescription of target zone for exercise was adopted the protocol proposed by Karvonen et al. (17). The heart rate of rest and during the exercise was evaluated utilizing by cardiofrequencymeter (RS800CX, Polar Electro® Oy, Kempele, Finland)

Measures of Blood Pressure: after the volunteers arrived on laboratory, they were oriented to stay in rest seated during 10 minutes to measures of blood pressure on end of this period. Others measures were realized during the 120 minutes of post-exercise recovery, each 10minutes. The first 30 minutes of post-exercise recovery the measures were always performed one minute before coffee administration. The blood pressure was measured by auscultatory method, following the protocol proposed by VI Brazilian Guidelines of Arterial Hypertension (18). For this, was utilized one sphygmomanometer (Missouri, Embu, Brasil), previously calibrated against one mercury column and one stethoscope (Missouri, Embu, Brasil).

Statistical Analysis: all the data are presented as mean±standard-error of mean. All variables were tested for normal distribution using Shapiro-Wilk and Levene tests. For the comparisons of age, body mass index, heart rate of rest, systolic and diastolic blood pressure of rest between the experimental sessions was utilized one-way ANOVA. For the comparisons of systolic and diastolic post-exercise between the experimental sessions of study was realized two-way ANOVA plus Bonferroni test post hoc. P value small than 0,05 was considered statically significant.

Study Type

Interventional

Enrollment (Actual)

12

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Were included subjects of both gender (three men), 40 to 55 years old, overweight and practitioners of aerobic exercise (walk) at least three months. They were treated with anti-hypertensive medication of class beta-adrenergic receptor blockers, thiazides and enzyme convertor of angiotensin inhibitors, and showing systolic and diastolic values controlled and habituated to coffee consumption.

Exclusion Criteria:

  • Would be excluded from the study volunteers who presented migraine or other withdrawal symptoms due to a washout to be carried out for coffee and other caffeinated foods.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: One dose of coffee
Ingestion of one dose of 150 ml of coffee (144 mg of caffeine) ingested 10 minutes post-exercise (denominated CAF-1)
In this intervention the volunteers ingested one dose of caffeinated coffee containing 144 mg of caffeine
Experimental: Two doses of coffee
Ingestion of two doses of 150 ml of coffee (144 mg of caffeine) ingested 10 and 20 minutes post-exercise (denominated CAF-2)
In this intervention the volunteers ingested two doses of caffeinated coffee containing 288 mg of caffeine
Experimental: Three doses of coffee
Ingestion of three doses of 150 ml of coffee (144 mg of caffeine) ingested 10, 20 and 30minutes post-exercise (denominated CAF-3)
In this intervention the volunteers ingested three doses of caffeinated coffee containing 432mg of caffeine
Experimental: Three doses of decaffeinated coffee
Ingestion of three doses of 150 ml of decaffeinated coffee (144 mg of caffeine) ingested 10, 20 and 30 minutes post-exercise (denominated DESC)
In this intervention the volunteers ingested one dose of decaffeinated coffee containing 108 mg of caffeine

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Systolic and diastolic blood pressure. The measures were evaluated for delta (difference between the values obtained in the period of recovery and baseline)
Time Frame: The systolic and diastolic blood pressure were measured in CAF-1, CAF-2, CAF-3 and DESC after the baseline and during 120 minutes post-exercise each 10 minutes. Thus, were realized 13 measures of blood pressure in each experimental session.
The sessions CAF-1, CAF-2, CAF-3 and DESC were realized with interval of 72 hours between them, thus, each volunteer devoted an average 20 days to the study.
The systolic and diastolic blood pressure were measured in CAF-1, CAF-2, CAF-3 and DESC after the baseline and during 120 minutes post-exercise each 10 minutes. Thus, were realized 13 measures of blood pressure in each experimental session.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2011

Primary Completion (Actual)

May 1, 2014

Study Completion (Actual)

November 1, 2014

Study Registration Dates

First Submitted

December 23, 2014

First Submitted That Met QC Criteria

January 7, 2015

First Posted (Estimate)

January 12, 2015

Study Record Updates

Last Update Posted (Estimate)

January 12, 2015

Last Update Submitted That Met QC Criteria

January 7, 2015

Last Verified

January 1, 2015

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertension

Clinical Trials on CAF-1

Subscribe